MNPR · CIK 0001645469 · operating
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing oncology-focused therapeutics. The company's pipeline includes ALXN1840, an oral once-daily investigational medicine in late-stage development, and MNPR-101, a proprietary humanized monoclonal antibody platform conjugated with different radioisotopes to target urokinase plasminogen activator receptor expressed on advanced solid tumors. The MNPR-101 platform encompasses both diagnostic and therapeutic applications, including MNPR-101-Zr for radiodiagnostic imaging and MNPR-101-Lu for radiotherapeutic use in late-preclinical development.
The company maintains a collaboration with NorthStar to develop radio-immuno-therapeutics for severe COVID-19 treatment. Monopar has no disclosed revenue streams as a clinical-stage entity without approved products.
Based in Wilmette, Illinois, the company operates with a minimal team of 14 full-time employees, typical of early-stage biopharmaceutical firms focused on research and development. Monopar was incorporated in Delaware and founded in 2014, with its shares listed on the Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | — | $-4.11 | -573.8% | |
| 2023 | — | $-0.61 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001437749-25-009979 | SEC ↗ |
| 2023-12-31 | 2024-03-28 | 0001437749-24-009687 | SEC ↗ |
| 2022-12-31 | 2023-03-23 | 0001654954-23-003384 | SEC ↗ |
| 2021-12-31 | 2022-03-24 | 0001654954-22-003701 | SEC ↗ |
| 2020-12-31 | 2021-03-25 | 0001654954-21-003243 | SEC ↗ |
| 2019-12-31 | 2020-03-27 | 0001654954-20-003363 | SEC ↗ |
| 2018-12-31 | 2019-02-26 | 0001654954-19-002003 | SEC ↗ |
| 2017-12-31 | 2018-03-26 | 0001654954-18-003136 | SEC ↗ |